EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial

Satoshi Kuwabara iD, Susumu Kusunoki, Motoi Kuwahara, Yoshihisa Yamano, Yoichiro Nishida, Hirokazu Ishida, Tomoyuki Kasuya, Erik Kupperman, Qun Lin, Glen Frick, Sonoko Misawa

Journal of the Peripheral Nervous System · 2024-09 · 29 (3) · 339-349

DOI: 10.1111/jns.12646 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 10.07.2024. Verfasst von Satoshi Kuwabara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Guillain-Barre Syndrome. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Guillain‐Barré syndrome (GBS) is an acute, self‐limited, immune‐mediated peripheral neuropathy. Current treatments for GBS include intravenous immunoglobulin (IVIg) and plasma exchange, which may not sufficiently benefit severely affected patients. This study evaluated the efficacy and safety of eculizumab add‐on therapy to IVIg (standard‐of‐care treatment) in patients with severe GBS.

Methods

This phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial (NCT04752566), enrolled Japanese adults (age ≥ 18 years) with severe GBS (Hughes functional grade [FG] score FG3 or FG4/FG5 within 2 weeks of onset of GBS). Participants were randomized 2:1 to receive intravenous infusion of eculizumab or placebo (once weekly for 4 weeks) with IVIg treatment with 20 weeks of follow‐up. Primary efficacy endpoint was the time to first reach FG score ≤1 (able to run). Key secondary endpoints were proportion of participants achieving FG ≤1 at weeks 8 and 24 and FG improvement ≥3 at week 24. Pharmacodynamic analysis of serum free C5 concentration over time was performed. Safety was evaluated.

Results

The analysis included 57 participants (eculizumab, n = 37; placebo, n = 20). Primary endpoint was not achieved (hazard ratio, 0.9; 95% CI, 0.45–1.97; p = .89). Key secondary endpoints did not reach statistical significance. Serum C5 concentration was reduced by 99.99% at 1 h postdose and sustained to week 5 but returned to baseline at the end of follow‐up period. No new safety signals for eculizumab were identified.

Interpretation

Although well tolerated, eculizumab treatment did not show significant effects on motor function recovery compared to placebo in patients with GBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGuillain-Barre SyndromeHumansMaleDouble-Blind MethodFemaleMiddle AgedAdultAgedImmunoglobulins, IntravenousComplement Inactivating AgentsTreatment Outcome

Stichwörter der Autor:innen

Guillain‐Barré syndromeJapancomplement inhibitioneculizumabsafety

Substanzen

Antibodies, Monoclonal, HumanizedeculizumabImmunoglobulins, IntravenousComplement Inactivating Agents

Autor:innen und Institutionen

  • Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Neurology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
  • Department of Neurology, St. Marianna University School of Medicine Kawasaki, Japan.
  • Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
  • Alexion Pharma GK, Tokyo, Japan.
  • AstraZeneca Rare Disease, Alexion, Boston, USA.

ORCID-Profile: Satoshi Kuwabara

Förderung

  • Alexion, AstraZeneca Rare Disease
  • Alexion Pharmaceuticals

Zitieren

APA

Kuwabara, S., Kusunoki, S., Kuwahara, M., Yamano, Y., Nishida, Y., Ishida, H., Kasuya, T., Kupperman, E., Lin, Q., Frick, G., & Misawa, S. (2024). Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial. Journal of the Peripheral Nervous System, 29(3), 339-349. https://doi.org/10.1111/jns.12646

Vancouver

Kuwabara S, Kusunoki S, Kuwahara M, Yamano Y, Nishida Y, Ishida H, et al. Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial. Journal of the Peripheral Nervous System. 2024;29(3):339-349. doi:10.1111/jns.12646

BibTeX
@article{Kuwabara2024,
  author = {Kuwabara, Satoshi and Kusunoki, Susumu and Kuwahara, Motoi and Yamano, Yoshihisa and Nishida, Yoichiro and Ishida, Hirokazu and Kasuya, Tomoyuki and Kupperman, Erik and Lin, Qun and Frick, Glen and Misawa, Sonoko},
  title = {Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial},
  journal = {Journal of the Peripheral Nervous System},
  year = {2024},
  volume = {29},
  number = {3},
  pages = {339--349},
  doi = {10.1111/jns.12646}
}
Kostenlos starten →